Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.' - 2South Africa collects record $117B tax haul
- 3Two Passover initiatives target isolation and safety for Israel’s elderly
- 4An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- 5Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- 6 Shades Brands For Seniors
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- Space station changes command, setting stage for Crew 11 departure
- Astronauts beam home Christmas wishes from International Space Station: 'I think we may be orbiting a little higher than Santa' (video)
- Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- German gas price bill signed into law, but consumers not impressed
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Gym tied to outbreak of obscure disease that spreads through mist
